Skip to main content

Table 3 Prespecified definitions for medication use at baseline

From: Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial

Medication

ATC codes

Number of prescriptions

Timeframe

Antithrombotics

B01

≥ 1 claimed prescription

≤ 180 days prior to randomization

Renin-angiotensin system inhibitor

C09

≥ 1 claimed prescription

≤ 180 days prior to randomization

Calcium blockers

C08

≥ 1 claimed prescription

≤ 180 days prior to randomization

Beta blockers

C07

≥ 1 claimed prescription

≤ 180 days prior to randomization

Diuretics

C03

≥ 1 claimed prescription

≤ 180 days prior to randomization

Aspirin

B01AC06

≥ 1 claimed prescription

≤ 180 days prior to randomization

Statins

C10AA

≥ 1 claimed prescription

≤ 180 days prior to randomization

Inhaled beta-2 agonists

R03A

≥ 1 claimed prescription

≤ 180 days prior to randomization

Inhaled anticholinergics

R03BB, R03AL01-07

≥ 1 claimed prescription

≤ 180 days prior to randomization

Inhaled glucocorticoids

R03BA, R03AK, R03AL08-09, R03AL11-12

≥ 1 claimed prescription

≤ 180 days prior to randomization

Insulin

A10A

≥ 1 claimed prescription

≤ 180 days prior to randomization

Non-insulin antidiabetic medication

A10B

≥ 1 claimed prescription

≤ 180 days prior to randomization

Systemic glucocorticoids

H02AB

≥ 1 claimed prescription

≤ 180 days prior to randomization

Immunosuppres-sants

L04

≥ 1 claimed prescription

≤ 180 days prior to randomization

  1. Medication use at baseline will be assessed using ATC codes. ATC anatomic therapeutical chemical